DNA damage induced by reactive oxygen species (ROS) [1][2][3] . A primary cause of ROS-2 induced cell death is the accumulation of DNA double-strand breaks (DSBs) 1,4-6 . DNA 3 polymerase IV (pol IV), an error-prone DNA polymerase produced at elevated levels in 4 cells experiencing DNA damage, has been implicated both in ROS-dependent killing 5 and in DSBR [7][8][9][10][11][12][13][14][15] . Here, we show using single-molecule fluorescence microscopy that 6 ROS-induced DSBs promote pol IV activity in two ways. First, exposure to the 7 antibiotics ciprofloxacin and trimethoprim triggers an SOS-mediated increase in 8 intracellular pol IV concentrations that is strongly dependent on both ROS and DSBR. 9
substrates. 48
Reasoning that the decreased induction of DinB-YPet expression in cells co-treated 1 with DMSO likely resulted from attenuation of the SOS response, we repeated the time-2 lapse experiments on cells that carried an SOS-reporter plasmid, in which GFP is expressed 3 from the SOS-inducible sulA promoter (pUA66 PsulA-GFP; fast-folding GFP, gfpmut2 41 ). In 4 the absence of any antibiotic treatments, cells exhibit very low fluorescence intensity, 5
consistent with the repression of the sulA promoter in the absence of exogenous sources of 6 DNA damage (Figure 3 , '0 min'). SOS levels were similarly low for cells grown in the 7 presence of DMSO. Cells exhibited robust SOS induction upon treatment with ciprofloxacin 8
as evidenced by the increase in GFP fluorescence in the three hour time window after 9 addition of ciprofloxacin (Figure 3b) . Consistent with our hypothesis, SOS induction was 10 strongly inhibited upon inclusion of DMSO during ciprofloxacin treatment (7% of 11 ciprofloxacin-alone levels at 180 min; Figure 3b) . Similarly, high levels of SOS induction in 12 trimethoprim treated cells were supressed by the addition of DMSO (0.6% of ciprofloxacin-13 alone levels; Figure 3b) . Notably, the addition of a different ROS scavenger, 2,2'-bipyridine 14
(BiP, 0.35 mM, 0.5 x MIC 5 ), similarly supressed the induction of the SOS response ( Figure  15 3). 16 We further reasoned that the suppression of SOS by ROS scavengers might reflect a 17 reduction in the formation and processing of DSBs. It was previously observed that induction 18 of SOS by the antibiotic nalidixic acid was completely blocked in cells that carried a recB 19 mutation and were therefore incapable of processing DSBs through the RecBCD end-20 resection nuclease complex 30, 31 . This implies that SOS is primarily triggered by DSB 21 processing in nalidixic acid-treated cells. As ciprofloxacin and nalidixic acid both target DNA 22 gyrase 32,33,42 , we repeated the GFP reporter measurements in cells lacking recB (SSH111, 23
ΔrecB PsulA-GFP) to determine if SOS induction by ciprofloxacin is also dependent on DSB 24
processing. The deletion of recB strongly inhibited the SOS response following ciprofloxacin 25 treatment (~0.4% induction at 180 min in comparison to recB + , Figure 3 , Supplementary  26  figure 4 ). While recB deletions are known to reduce survival in cells treated with 27 ciprofloxacin 43 , we observed that most cells lacking recB continued to grow and divide during 28 the 180 min time-lapse measurement (Supplementary figure 3,4) , indicating that the lack of 29 SOS induction observed for ciprofloxacin-treated recB-deficient cells did not stem from gross 30 inhibition of all cellular functions. Thus, induction of the SOS response is dependent on DSB 31 processing in cells treated with ciprofloxacin. Together the results are consistent with a 32 model in which the SOS response is triggered in antibiotic-treated cells via ROS-induced 33
DSBs, leading to increased levels of pol IV in cells. 34 We next considered the possibility that pol IV plays a direct role in DSBR. To this end 35
we examined rates of DinB-YPet focus formation in cells treated with ciprofloxacin and 36
trimethoprim, comparing conditions that permitted DSB resection (recB + , no DMSO) or 37
prevented DSB resection (co-treatment with DMSO to supress ROS-induced DSB formation, 38
or ΔrecB to prevent resection). To separate effects on focus formation from effects on DinB-39
YPet expression, these measurements were carried out in a lexA(Def) background 44 (dinB-40
YPet dnaX-mKate2 lexA [Def] ). These cells constitutively express DinB-YPet at levels 41 consistent with SOS induced levels, even in the absence of DNA damage 28 . Consistent with 42
the results from our previous study 28 , close to zero DinB-YPet foci were observed in 43 lexA(Def) cells in the absence of antibiotic (0.08 ± 0.05 foci per cell, Figure 4) . lexA(Def) 44 cells treated with ciprofloxacin for 60 min exhibited clear foci (1.43 ± 0.15 foci per cell, 45 Figure 4b ). Co-treatment with ciprofloxacin and DMSO yielded fewer foci (1.02 ± 0.13 foci 46 per cell, Figure 4b ). In ΔrecB, cells contained 0.23 ± 0.05 foci per cell. Cells treated with 47 trimethoprim for 60 min contained DinB-YPet foci (2.6 ± 0.18 foci per cell), whereas cells 48 treated with both trimethoprim and DMSO contained few foci (0.19 ± 0.06). Trimethoprim-1 treated ΔrecB cells also contained very few foci (0.14 ± 0.05). Similar effects were observed 2 in lexA + cells, although reductions in focus formation were conflated with reductions in DinB-3
YPet expression levels (Figure 2c) . Together, these results indicate that reducing the 4 number of ROS-induced DSBs being formed, and inhibiting DSB resection, upon antibiotic 5 treatment led to reduced focus formation by DinB-YPet. This implies that pol IV is normally 6 active at ROS-induced DSBs in cells treated with ciprofloxacin or trimethoprim. Importantly, 7
RecBCD function is critical for pol IV activity. 8
In ciprofloxacin-treated cells, 10% of pol IV foci form in the vicinity of replisomes 28 . 9
Here we observed that in addition to reducing the number of DinB-YPet foci, DMSO 10 treatment dramatically increased the relative colocalisation of DinB-YPet with replisomes in 11
both lexA + and lexA(Def) cells treated with ciprofloxacin (Supplementary figure 5, 6) . For 12 long-lived pol IV foci (detectable within a 10s average projection image) in the lexA(Def) 13
background, 80% of foci colocalised with replisomes under ciprofloxacin-DMSO conditions 14 (Supplementary figure 6b) . This is consistent with the addition of DMSO having removed 15 the vast majority of non-replisomal substrates for pol IV-dependent DNA synthesis. For 16 lexA(Def) cells treated with trimethoprim, addition of DMSO abolished long-lived pol IV foci 17 entirely (Supplementary figure 6a, treatment (with or without DMSO) did not lead to activation of pol V: UmuC-mKate2 failed to 30 undergo its characteristic spatial redistribution 39 , remaining bound to the cell membrane 31 (Supplementary figure 8a, c) . Consistent with this, cleavage of UmuD to UmuD′ was far 32 less efficient in trimethoprim-treated cells than in ciprofloxacin-treated cells (compare 33
Supplementary figure 9b and d) . 34 We conclude that the processing of ROS-induced DSBs induces high intracellular 35
concentrations of DinB-YPet and promotes focus formation. The observations are consistent 36 with a model in which ROS-induced DSBs promote pol IV activity by inducing the SOS 37 response and by generating substrates for pol IV in the form of recombination intermediates.
38
Few DinB-YPet foci were observed in cells treated with a combination of trimethoprim and 39 DMSO (Figure 4) . Based on events that occur during the analogous process of thymineless 40 death 5,45 , treatment with trimethoprim should induce the formation of ssDNA gaps in the 41 wake of the replisome. In the presence of ROS these would be rapidly converted to DSBs, 42
whereas in the presence of ROS scavengers the gaps would persist. The low extent of focus 43
formation observed under trimethoprim-DMSO conditions implies that pol IV rarely acts at 44 these ssDNA gaps. In contrast, the formation of foci by the pol V was not affected by the 45 addition of DMSO (Supplementary figure 7) . This implies that ssDNA gaps might represent 46 a major substrate for pol V and that DSB intermediates are rarely acted upon by pol V. In 47 cells treated with ciprofloxacin, the colocalisation of DinB-YPet with replisomes was 48 6 substantially increased in the presence of DMSO. Ciprofloxacin induces the formation of 1 end-stabilised DNA-gyrase complexes, which slow cell growth but are non-lethal 46 . It is 2 possible that replisome-proximal DinB-YPet foci, that are insensitive to ROS, reflect pol IV 3 molecules that are recruited to replisomes that have stalled at end-stabilised DNA-gyrase 4 complexes. 5 6
Methods

7
Strain construction 8
EAW102 is E. coli K-12 MG1655 ΔrecB and was constructed using λ RED 9
recombination. The kanamycin resistance marker in EAW102 was removed via FLP-FRT 10 recombination 47 using the plasmid pLH29 to obtain kanamycin sensitive HG356. Cells were grown in LB overnight at 37ºC. The next day, a 1/100 dilution of each 2 culture was grown in LB medium (at 37ºC, 150 rpm) until reaching mid log phase (OD 600 = 3 0.2). Cell cultures were then serially diluted in PBS by factors of ten down to 10 -5 . Serial 4 dilutions were spotted (spot volume 10 µL) on fresh LB plates (Difco brand) and LB plates 5 containing DNA damaging agent (which were protected from light). For Supplementary  6 figure 1, DNA damaging agents were added at the following concentrations: 0.1 µg/mL 7 trimethoprim; 12 ng/mL ciprofloxacin. For Supplementary figure 2, DNA damaging agents 8
were added at the following concentrations: 0.1 µg/mL or 0.2 µg/mL trimethoprim; 10 ng/mL 9 or 12 ng/mL ciprofloxacin. Some survival essays were performed under radical-scavenging 10
conditions. Additionally to the particular antibiotic, DMSO (2% v/v, 282 mM, 0.2 x MIC 5 ) was 11 then also added to the plates. Plates were incubated at 37ºC in the dark. 12
Trimethoprim survival assay 1
Cells were grown in LB overnight at 37⁰C. The next day, a 1/100 dilution of each 2 culture was grown in 5 mL LB medium (at 37⁰C, 150 rpm) until reaching mid log phase 3
(OD 600 = 0.3). Then, trimethoprim was added to 1 µg/mL followed by incubation at 37⁰C, 4 150 rpm. Samples of 500 µL were taken at 0, 0.5, 1, 2, 3 and 5 h; samples at 0h were taken 5 just before trimethoprim addition. Each sample was centrifuged and resuspended in 500 µL 6 LB; this was done twice to dilute out trimethoprim. Then, 50 µL of 500 µL were plated on LB 7 agar plates; three technical replicates were made for each time point and strain. Plates were 8 incubated at 37⁰C in the dark. The next day, colonies were counted and CFU/mL were 9 calculated for each time point; the average over the technical replicates was then calculated. 10
Two biological replicates were performed. Data points represent the average over the 11 biological duplicates. Error bars represent standard error of the mean over two biological 12
replicates. 13
Fluorescence microscopy 14
Wide-field fluorescence imaging was conducted on an inverted microscope (IX-81, 15
Olympus with a 1.49 NA 100x objective) in an epifluorescence configuration. Continuous 16 excitation is provided using semidiode lasers (Sapphire LP, Coherent) of the wavelength 514 17 nm (150 mW max. output) and 568 nm (200 mW max. output). DnaX-mKate2 in EAW643 18
and UmuC-mKate2 in EAW282 were imaged using yellow excitation light (λ = 568 nm) at 19
high intensity (2750 Wcm -2 ), collecting emitted light between 610-680 nm (ET 645/75m filter, 20
Chroma) on a 512 × 512 pixel EM-CCD camera (C9100-13, Hamamatsu). Images of UmuC-21 mKate2 in RW1286 were recorded at 275 Wcm -2 . For DinB-YPet imaging of EAW643, we 22 used green excitation (λ = 514 nm) at 160 Wcm -2 collecting light emitted between 525-555 23 nm (ET540/30m filter, Chroma). For DinB-YPet imaging of RW1594, cells were imaged at 24 51 Wcm -2 . DnaX-YPet imaging (EAW282, RW1286) was performed at 51 Wcm -2 . Cells 25 carrying the SOS reporter plasmid pUA66-sulA-GFP (SSH091, SSH111) were imaged at 16 26
Wcm -2 . 27 Two-colour time-lapse movies were recorded to visualise if DinB-YPet foci overlap 28
with DnaX-mKate2 foci (EAW643). Sets of three images were recorded (bright-field [34 ms 29 exposure], mKate2 fluorescence [100 ms exposure], YPet fluorescence [50 ms exposure]) at 30 an interval of 10 min for 3h. To measure colocalisation between UmuC-mKate2 with the 31 replisome marker DnaX-YPet (EAW282), we recorded time-lapse movies at the same 32 intervals but different exposures for the replisome marker (bright-field [34 ms exposure], 33 mKate2 fluorescence [100 ms exposure], YPet fluorescence [500 ms exposure]).
34
Burst acquisitions of DinB-YPet (movies of 300 × 50 ms frames taken every 100 ms 35
light at 514 nm) were collected, subsequently to each burst acquisition, an image of DnaX-36 mKate2 (568 nm) was taken (imaging sequence for RW1594). With this imaging sequence, 37
we analysed activity of DinB-YPet at replisomes. RW1286 was imaged similarly; we 38 recorded burst acquisitions of UmuC-mKate2 (568 nm) followed by a snapshot of DnaX-39
YPet (514 nm). All images were analysed with ImageJ 52 . 40
Flow cell designs 41
All imaging experiments were carried out in home-built quartz-based flow cells. 42
These flow cells were assembled from a no. 1.5 coverslip (Marienfeld, REF 0102222), a 43 quartz top piece (45x20x1 mm) and PE-60 tubing (Instech Laboratories, Inc.). Prior to flow-44 cell assembly, coverslips were silanised with (3-aminopropyl)triethoxysilane (Alfa Aeser).
45
First, coverslips were sonicated for 30 min in a 5M KOH solution to clean and activate the 46 surface. The cleaned coverslips were rinsed thoroughly with MilliQ water and then treated 1 with a 5% (v/v) solution of (3-aminopropyl)triethoxysilane (APTES) in MilliQ water. The 2 coverslips were subsequently rinsed with ethanol and sonicated in ethanol for 20 seconds. 3 Afterwards, the coverslips were rinsed with MilliQ water and dried in a jet of N 2 . Silanised 4 slides were stored under vacuum prior to use. 5
To assemble each flow cell, polyethylene tubing (BTPE-60, Instech Laboratories, 6
Inc.) was glued (BONDiT B-482, Reltek LLC) into two holes that were drilled into a quartz 7 piece. After the glue solidified overnight, double-sided adhesive tape was stuck on two 8 opposite sides of the quartz piece to create a channel. Then, the quartz piece was stuck to 9
an APTES-treated coverslip. The edges were sealed with epoxy glue (5 Minute Epoxy, 10 PARFIX). Each flow cell was stored in a desiccator under mild vacuum while the glue dried. 11
Typical channel dimensions were 45 mm × 5 mm × 0.1 mm (length × width × height). 12
Imaging in flow cells 13
For all imaging experiments, cells were grown at 37⁰C in EZ rich defined medium 14 (Teknova) that contained 0.2% (w/v) glucose. All strains that have a Kan R cassette were 15 grown in the presence of kanamycin (20 µg/mL). Cultures used for imaging under radical-16 scavenging conditions were grown in the presence of the particular scavenger used for the 17
Cells were loaded into flow cells, allowed a few minutes to associate with the APTES 20 surface, then loosely associated cells were removed by pulling through fresh medium. The 21 experiment was then initiated by adding either an antibiotic alone or in combination with 22
DMSO to the medium (30 ng/ mL ciprofloxacin, 30 ng/ mL ciprofloxacin with 2% (v/v) DMSO, 23
1 µg/mL trimethoprim, 1 µg/mL trimethoprim with 2% (v/v) DMSO or 1 µg/mL trimethoprim 24 with 0.35 mM BiP). Throughout the experiment, medium was pulled through the flow cell 25 using a syringe pump, at a rate of 50 µL/min. For each condition, triplicate measurements 26 were recorded. 27
Analysis of cell filamentation, concentrations, SOS induction level and number of foci 28
We selected single cells to obtain information about SOS induction, DinB and UmuC 29 levels upon UV irradiation (>100 cells for every time point). MicrobeTracker 0.937 53 , a 30
MATLAB script, was used to create cell outlines as regions of interest (ROI). We manually 31 curated cell outlines designated by MicrobeTracker at t = 0 min (time point of antibiotic 32 addition) and at 30 min time intervals until 180 min. By obtaining cell outlines manually, we 33 ensure accuracy and purely select non-overlapping, in-focus cells for analysis. These ROI 34
were imported in ImageJ 1.50i. The cell outlines were then used to measure mean cell 35
intensities, cell lengths and the number of foci per cell. Parameters describing foci (number, 36 positions and intensities) were obtained using a Peak Fitter plug-in, described previously 37 28,39 . 38
Analysis of colocalisation events 39
Foci were classed as colocalised if their centroid positions (determined using our 40 peak fitter tool) fell within 2.18 px (218 nm) of each other. When treating with ciprofloxacin, 41
we determined that for DinB-YPet-DnaX-mKate2 localisation the background of DinB foci 42 expected to colocalise with replisomes purely by chance is ~4% at 180 min. This was 43 calculated by taking the area of each cell occupied by replisome foci (including the 44 colocalisation search radius) and dividing by the total area of the cell. The value of 4% 45 corresponds to the mean of measurements made over 121 cells. Since the foci density of 46 1 of DinB-YPet foci with DnaX-mKate2 is ~4% during the experiment 28 . Chance colocalisation 2 of DnaX-mKate2 with DinB-YPet is however not constant over time because most cells 3 contain no pol IV foci in the absence of any DNA damage. Chance colocalisation is close to 4 zero at 0 min; at 60 min, chance colocalisation is ~5%; at 120 min, chance colocalisation is 5 ~3%. Moreover, chance colocalisation of DnaX-mKate2 with DinB-YPet is overall reduced 6 under radical-scavenging conditions due to a reduced number of foci per cell (chance 7 colocalisation close to zero at 0 min; at 120 min, ~2%). Chance colocalisation of DnaX-8 mKate2 with DinB-YPet in trimethoprim treated cells amounts to ~1% from 60-90 min (close 9 to zero before 60 min). Under radical-scavenging conditions, chance colocalisation is always 10 close to zero because the number of pol IV foci per cell does not increase post treatment as 11
well as cell size (Figure 2) . 12
The chance colocalisation of UmuC-mKate2 with DnaX-YPet is similar to the chance 13 colocalisation of DinB-YPet with DnaX-mKate2 (chance colocalisation: ~4%). The expected 14 colocalisation of DnaX-YPet with UmuC-mKate2 by background is close to zero until 90 min. 15
UmuC-mKate2 is neither upregulated nor released from the membrane ( Supplementary  16  figure 8a ). Chance colocalisation is ~3% at 180 min after ciprofloxacin treatment and ~2% 17
after the combinational treatment of ciprofloxacin/DMSO. 18
Western blotting 19
Overnight E. coli LB cultures of RW120/pRW154 and RW546/pRW154 50 were diluted 20 1 to 100 in fresh LB with appropriate antibiotics and grown to mid-log (~OD 0.5, ~3 hrs). 21
Aliquots were then taken for the untreated samples. and ΔumuDC) were grown to exponential growth phase (OD 600 = 0.2), serial diluted, 20
Figure captions
and spotted onto LB agar plates +/-DMSO, plates containing 12 ng/mL ciprofloxacin 21 +/-DMSO and plates containing 0.1 ng/mL trimethoprim +/-DMSO. Under antibiotic 22
treatment, the addition of DMSO rescues survival by one to two orders of magnitude. 23
Cell constructs used in this study (dinB-YPet dnaX-mKate2 and umuC-mKate2 dnaX-24
YPet) exhibit a similar phenotype to WT. b, Trimethoprim survival assay. Cell cultures 25
(WT, ΔdinB, ΔumuDC, dinB-YPet dnaX-mKate2 and umuC-mKate2 dnaX-YPet) were 26 grown to exponential growth phase (OD 600 = 0.3). Then, trimethoprim was added to 27 1 µg/mL. At each time point (0, 0.5, 1, 2, 3 and 5 h), 500 µL culture was taken, twice 28 centrifuged and resuspended in 500 µL LB. Finally, 50 µL were plated on LB agar 29 plates; three technical replicates were made. Plates were incubated at 37⁰C in the 30 dark. Colonies were counted and CFU/mL were calculated for each time point as an 31 average over the technical replicates. Error bars represent standard error of the mean 32 over two biological replicates. BiP. j, SSH111 cells (ΔrecB PsulA-GFP) treated with ciprofloxacin. We conservatively 20 estimate that >100 cells were used in each measurement. WT ∆dinB ∆umuDC 0 10 -1 10 -2 10 -3 10 -4 10 -5 0 10 -1 10 -2 10 -3 10 -4 10 -5 LB 12 ng/mL ciprofloxacin 12 ng/mL ciprofloxacin + DMSO 0 10 -1 10 -2 10 -3 10 -4 10 -5 A B 0 10 -1 10 -2 10 -3 10 -4 10 -5 0 10 -1 10 -2 10 -3 10 -4 10 -5 LB 12 ng/mL ciprofloxacin 12 ng/mL ciprofloxacin + DMSO 0 10 -1 10 -2 10 -3 10 -4 10 -5
WT ∆dinB ∆umuDC 0 10 -1 10 -2 10 -3 10 -4 10 -5 0 10 -1 10 -2 10 -3 10 -4 10 -5 LB 0.1 µg/mL trimethoprim 0.1 µg/mL trimethoprim + DMSO WT ∆dinB ∆umuDC 0 10 -1 10 -2 10 -3 10 -4 10 -5 C WT ∆dinB ∆umuDC 0 10 -1 10 -2 10 -3 10 -4 10 -5 0 10 -1 10 -2 10 -3 10 -4 10 -5 LB 0.2 µg/mL trimethoprim 0.2 µg/mL trimethoprim + DMSO 
